Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Responses to immunotherapy in hepatocellular carcinoma patients with nonalcoholic steatohepatitis cirrhosis.
Authors
Jeremy Chang
UC San Diego, La Jolla, CA
Jeremy Chang , Joseph S Ryan , Veeral Ajmera , Stephanie Ting , Pablo Tamayo , Adam Burgoyne
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
DOI
10.1200/JCO.2022.40.4_suppl.389
Abstract #
389
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Impact of Hispanic ethnicity on immunotherapy outcomes in hepatocellular carcinoma: Insights from the National Cancer Database.
First Author: Sumit Gaur
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-line therapies in a Latino-rich cohort of US patients (pts) with hepatocellular carcinoma (HCC) and Child Pugh B (CPB) cirrhosis.
First Author: Moses Andrew Alfaro
Poster
2023 ASCO Annual Meeting
Durvalumab and tremelimumab for hepatocellular carcinoma in patients listed for a liver transplant.
First Author: Davendra Sohal
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Durvalumab and tremelimumab for hepatocellular carcinoma in patients listed for a liver transplant.
First Author: Davendra Sohal